Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatide

Expert Opin Pharmacother. 2018 Mar;19(4):317-318. doi: 10.1080/14656566.2018.1444882. Epub 2018 Mar 5.

Authors

Sarah Eggert¹, Esther Zimmermann², Kamilla Begtrup³

Affiliations

¹ a Global Medical Affairs , Novo Nordisk A/S , Søborg , Denmark.
² b Epidemiology , Novo Nordisk A/S , Søborg , Denmark.
³ c Biostatistics , Novo Nordisk A/S , Søborg , Denmark.

PMID: 29471700
DOI: 10.1080/14656566.2018.1444882

No abstract available

Publication types

Letter
Comment

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2
Glycated Hemoglobin
Humans
Hypoglycemia
Hypoglycemic Agents
Insulin Glargine*
Insulin, Long-Acting
Liraglutide*
Peptides

Substances

Blood Glucose
Glycated Hemoglobin A
Hypoglycemic Agents
Insulin, Long-Acting
Peptides
Insulin Glargine
insulin degludec
lixisenatide
Liraglutide